Our leadership team

Jason Rhodes

Chairman

Jason is a partner with Atlas Venture, where he focuses on creating and building novel therapeutics companies. He is a founder and the chairman of Dyne, Generation Bio (NASDAQ: GBIO), Rectify Pharmaceuticals, and Disarm Therapeutics (acquired by Lilly). He was also previously on the board of Replimune (NASDAQ: REPL).

Jason received his B.A. from Yale University and his M.B.A. from the Wharton School of the University of Pennsylvania.

Joshua Brumm

Josh brings extensive healthcare leadership experience to his role at Dyne. Previously, he served as chief operating officer and chief financial officer of Kaleido Biosciences, where he led the company’s financings including its initial public offering and helped bring the lead program into Phase 2 development. Prior to joining Kaleido, Josh was COO and CFO at Versartis, where he spearheaded the company’s financial strategy including the successful completion of its IPO, played an integral role in product strategy, and helped negotiate the company’s first product partnership. His previous roles include serving as executive vice president of finance and principal financial officer at Pharmacyclics; CFO at ZELTIQ Aesthetics, where he led the company through its initial public offering, led the international product launch for CoolSculpting and also served in corporate development; and director of finance at Proteolix, Inc., assisting in the sale of the company to Onyx Pharmaceuticals. He also held investment banking roles at Citigroup Global Markets, Inc. and Morgan Stanley. Over the course of his career, Josh has raised approximately $2 billion in capital. Josh serves as Chairman of the Board of Amphista Therapeutics, a company focused on advancing targeted protein degradation therapeutics.

He holds a B.A. in business administration from the University of Notre Dame.

Ed Hurwitz

Ed is an accomplished biotechnology executive and investor who currently serves as managing director of Precision BioVentures, since he founded the firm in 2013. Previously, he was a managing director at MPM Capital and serves on the boards of several MPM portfolio companies, including Dyne. Prior to MPM his roles include serving as a director at Alta Partners, where he led 12 successful investments, and as a senior vice president and chief financial officer of Affymetrix, a microarray supplier. Ed also practiced law at Cooley Godward LLP and was a biotechnology research analyst for Robertson Stephens & Company and Smith Barney Shearson.

Ed earned his J.D. and M.B.A. degrees from the University of California, Berkeley, and his B.A. in molecular biology from Cornell University.

Carlo Incerti, M.D.

Carlo has more than three decades of experience in the biopharmaceutical industry, including in rare disease drug development. Carlo is currently an operating partner at Forbion, a life sciences venture capital firm. Previously, he held several positions of increasing responsibility during his more than 25 years at Sanofi Genzyme, including senior vice president, chief medical officer and head of global medical affairs. He also served as senior vice president of global market access and held various roles at Genzyme’s European headquarters. He is chairman of the Board at Inversago Pharma, EryDel SpA, Azafaros B.V., VectorY Therapeutics, and a member of the Board of Numab Therapeutics AG. Carlo is also a founding member of the International Rare Diseases Research Consortium.

He received his medical degree from the University of Modena and Reggio Emilia, Italy.

Dirk Kersten

Dirk is a general partner at Forbion, a leading European life science venture capital firm, where he focuses primarily on new investments. He is a physicist by training and previously was a partner at Gilde Healthcare Partners, where he led U.S. operations. Previously, Dirk was a managing director at INKEF Capital, where he was responsible for all healthcare investment activities. Dirk led a series of investments in Europe and the U.S. and was an active board member at a number of life science companies, including Ascendis Pharma, Lanthio Pharma (acquired by Morphosys), Profibrix (acquired by The Medicines Company) and Nightbalance (acquired by Royal Philips).

Dirk received his M.S. in physics from the University of Groningen in the Netherlands.

David Lubner

David Lubner is an accomplished financial leader in the life sciences space. He served as executive vice president and chief financial officer of Ra Pharma Inc., acquired by UCB in April 2020. Before joining Ra Pharma, David served as a member of the senior management team of Tetraphase Pharmaceuticals, Inc. and PharMetrics Inc., a leading patient-based pharmacy and medical claims data informatics company, which was acquired by IMS Health in 2005 and at ProScript, Inc., where Velcade^® (bortezomib), a therapy widely used for treatment of the blood cancer multiple myeloma, was discovered. He serves as a member of the board of directors of Arcellx Inc., Vor Biopharma, Inc. and Point Biopharma, Inc. and several other private companies. He previously served on the board of directors of Nightstar Therapeutics plc (acquired by Biogen), a company focused on the development of one-time retinal gene therapies for patients suffering from rare inherited retinal diseases, Therapeutics Acquisition Corporation and Gemini Therapeutics.

David is a Certified Public Accountant. He received his B.S. in business administration from Northeastern University and an M.S. in taxation from Bentley University.

Catherine Stehman-Breen

Catherine is currently chief executive officer and a member of the board of directors of Chroma Medicine, Inc. Previously, she was chief development officer at Obsidian Therapeutics and was an entrepreneur-in-residence with Atlas Venture. Before Atlas, she served as chief medical officer of Sarepta Therapeutics; vice president, clinical development at Regeneron Pharmaceuticals; and held senior leadership positions at Amgen, including as vice president, global development, where she led several therapeutic areas.

Catherine serves as a member of the board of directors of Generation Bio Co. and Tenaya Therapeutics, Inc. She earned her M.D. from the University of Chicago. She completed her residency and nephrology fellowship training at the University of Washington, where she also received an M.S. in epidemiology. Catherine served as a faculty member in the division of nephrology and remains an affiliate associate professor in the University of Washington School of Public Health, with more than 90 publications in medical journals.

Sudhir Agrawal, D.Phil.

Dr. Agrawal is a visiting professor in the Department of Medicine at the University of Massachusetts Medical School and a member of the advisory board of the Harvard Medical School Initiative for RNA Medicine. He is a founder and member of Arnay Sciences LLC. He is also a founder of Idera Pharmaceuticals, where he served in various leadership roles, including as chairman, CEO, president of research and chief scientific officer. Over the last three decades, his research has focused on the discovery and development of nucleic acid therapeutics, including antisense technology. He has published over 300 research papers and is listed as a co-inventor on more than 400 patents worldwide. He has edited four books on oligonucleotides and antisense technology, including “Advances in Nucleic Acid Therapeutics,” published in February 2019.

Dr. Agrawal received his Ph.D. in chemistry and conducted post-doctoral research at the MRC’s Laboratory of Molecular Biology in Cambridge, U.K.

Nancy Andrews, M.D., Ph.D.

Dr. Andrews is the former dean of the School of Medicine at Duke University, having served for 10 years in that role. Prior to her deanship, she was the G.R. Minot Professor and Dean for Basic Sciences and Graduate Studies at Harvard Medical School. Her research, funded by the Howard Hughes Medical Institute and the NIH, led to advances in understanding iron biology and iron diseases. She is an elected member of the National Academy of Sciences, the National Academy of Medicine and the American Academy of Arts and Sciences. Dr. Andrews also serves on the board of directors of the Burroughs Wellcome Fund, the American Academy of Arts and Sciences and Novartis AG, and is a member of the MIT Corporation.

Dr. Andrews received her B.S. and M.S. from Yale University, her M.D. from Harvard Medical School and her Ph.D. from the Massachusetts Institute of Technology. Her clinical training was at Boston Children’s Hospital and Dana-Farber Cancer Institute.

Louis Kunkel, Ph.D.

Dr. Kunkel is an internationally recognized geneticist who has devoted his career to understanding the molecular basis of, and developing novel therapies for, neuromuscular disorders. He is universally recognized for his 1986 identification of dystrophin as the causative gene in Duchenne muscular dystrophy. His current work centers on developing dystrophin independent therapies for Duchenne muscular dystrophy to complement existing therapies currently in development. A past Howard Hughes investigator and current member of the National Academy of Sciences, Dr. Kunkel has received numerous awards for his research, including the Welcome Trust Prize and the Gairdner Foundation International Award. He currently serves as a member of the Division of Genetics and Genomics at Boston Children’s Hospital, and as a professor of pediatrics and genetics at Harvard Medical School.

Dr. Kunkel received his B.A. from Gettysburg College and his Ph.D. from Johns Hopkins University.

Francesco Muntoni, FRCPCH, FMedSci

Dr. Muntoni’s research group led the development of the first genetic therapies in Duchenne muscular dystrophy (DMD) and continues to drive cutting-edge exploration of the genetic roots of and investigational therapies for DMD and spinal muscular atrophy. Throughout his career, Dr. Muntoni has identified more than 30 neuromuscular disease genes and supported more than 30 clinical trials and natural history studies in pediatric neuromuscular diseases. He currently chairs the pediatric neurology department at University College London (UCL) and directs the Dubowitz Neuromuscular Centre, a leading research and clinical trial site for children affected by neuromuscular disorders. At Great Ormond Street Hospital for Children, Dr. Muntoni serves as the theme lead for novel therapies at the Biomedical Research Centre.

Dr. Muntoni earned his M.D. from the Cagliari University Medical School in Italy. He completed a specialization in pediatric neurology and psychiatry at Sassari University Medical School in 1989. In addition to his role on Dyne’s Scientific Advisory Board, Dr. Muntoni serves as an advisor to Capricor Therapeutics, Sarepta Therapeutics and Pfizer.

Jeffrey Statland, M.D.

Dr. Jeff Statland is an associate professor of neurology at the University of Kansas Medical Center and a leading researcher in the field of facioscapulohumeral muscular dystrophy (FSHD). He is the co-principal investigator for ReSolve (Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD), an ongoing observational study that aims to validate new clinical outcome assessments and evaluate physiological biomarkers to support the design and implementation of future clinical trials. In addition to co-leading the ReSolve Natural History Study, Dr. Statland, with his collaborators at the University of Rochester Medical Center, is developing a disease-specific patient reported health inventory and molecular and neuroimaging biomarkers of disease activity for future FSHD clinical trials.

Dr. Statland holds a B.A. from Sarah Lawrence College, an M.F.A. from Emerson College and an M.D. from the University of Kansas School of Medicine. He completed residency training in the Department of Neurology at the University of Kansas Medical Center, and also conducted a fellowship in experimental therapeutics of neurologic disorders in the Department of Neurology at the University of Rochester Medical Center. He is board certified by the American Board of Psychiatry and Neurology.

Charles Thornton, M.D.